Sell-Side Analysts Ignore Burford’s (BUR) Massively Lucrative Protein Cases

Greenhaven Road Capital, an investment firm, disclosed its Q2 2026 results in its latest investor letter. The letter revealed an 11% net return for the quarter, showing improvement from the first quarter. The fund's strategy includes reducing portfolio concentration, investing in assets with near-term catalysts, and being proactive with profit-taking. Key holdings will be reviewed to identify the fund's best picks for 2026.

The letter specifically mentioned Burford Capital Limited, a litigation finance and asset management company. Burford Capital had a market capitalization of $959.58 million and a share price of $4.37 at the time of reporting. The company's litigation finance arm reported an 8.71% return for the month and a 52-week loss of 67.89%.

In a bullish thesis regarding Burford Capital, the fund highlighted that Burford is the leading player in litigation finance, having funded over 285 cases, with 90% resulting in wins or profitable settlements. The fund's investments in these cases generated an 82% return on invested capital over a weighted average life of 2.6 years, producing a 25% internal rate of return (IRR).

The investments were primarily in cases related to price-fixing involving proteins such as chicken, beef, turkey, and pork. The defendants in these cases are major companies like Tyson Foods, Pilgrim's Pride, Koch Foods, and Cargill, which have already spent billions settling antitrust claims. If these companies lose at trial, they may face treble damages, further incentivizing settlement.

Burford Capital's settlements could potentially exceed the company's market capitalization and could be realized within the next year as the cases proceed to trial.